Crossmark

Fostamatinib in chronic immune thrombocytopenia: a profile of its use in the USA

Crossref DOI link: https://doi.org/10.1007/s40267-018-0551-x

Published Online: 2018-08-29

Published Print: 2018-10

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

McKeage, Kate

Lyseng-Williamson, Katherine A.
License Information

Text and Data Mining valid from 2018-08-29
More Information

Article History

First Online: 29 August 2018

Change Date: 16 November 2018

Change Type: Correction

Change Details: The article Fostamatinib in chronic immune thrombocytopenia: a profile of its use in the USA, was originally published Online First without open access. After publication in volume 34, issue 10, pages 451–456, Rigel Pharmaceuticals, Inc. requested that the article be Open Choice to make the article an open access publication. Post-publication open access was funded by Rigel Pharmaceuticals, Inc. The article is forthwith distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License.

Compliance with ethical standards

:

: The preparation of this review was not supported by any external funding.

: K. McKeage and K.A. Lyseng-Williamson are employees of Adis/Springer, are responsible for the article content and declare no conflicts of interest.